Publications by authors named "Roger Lane"

Claim this Profile
D
Drug repurposing for Alzheimer's disease: a Delphi consensus and stakeholder consultation.
Anne Corbett, Janet Sultana, Kate Stych, Roger Mills, Jeff L Cummings, Roger Lane

Alzheimers Res Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human.
Lieuwe Appel, Robert Risinger, Anders Wall, Harald Murck, Shuang Liu, Roger Lane

Psychopharmacology (Berl)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series.
Neil A Shneider, Matthew B Harms, Vlad A Korobeynikov, Olivia M Rifai, Benjamin N Hoover, Roger Lane

Lancet· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Changes of Clinical, Imaging, and Fluid Biomarkers in Preataxic and Early Ataxic Spinocerebellar Ataxia Type 2 and 7 Carriers.
Giulia Coarelli, Charlotte Dubec-Fleury, Emilien Petit, Sabrina Sayah, Clara Fischer, Roger Lane

Neurology· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATXN7-Related Cone-Rod Dystrophy: The Integrated Functional Evaluation of the Cerebellum (CERMOI) Study.
Marco Nassisi, Giulia Coarelli, Benoit Blanchard, Charlotte Dubec-Fleury, Karima Drine, Roger Lane

JAMA Ophthalmol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers.
Roger M Lane, Taher Darreh-Shori, Candice Junge, Dan Li, Qingqing Yang

BMC Neurol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Tau-targeting antisense oligonucleotide MAPT in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Roger M Lane

Nat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial.
Amanda L Edwards, Jessica A Collins, Candice Junge, Holly Kordasiewicz, Laurence Mignon, Roger Lane

JAMA Neurol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tau-targeting antisense oligonucleotide MAPT in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Roger M Lane

Nat Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS.
Timothy Miller, Merit Cudkowicz, Pamela J Shaw, Peter M Andersen, Nazem Atassi, Roger Lane

N Engl J Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Huntingtin Expression in Patients with Huntington's Disease.
Sarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, Edward J Wild, Carsten Saft, Roger M Lane

N Engl J Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translating Antisense Technology into a Treatment for Huntington's Disease.
Roger M Lane, Anne Smith, Tiffany Baumann, Marc Gleichmann, Dan Norris

Methods Mol Biol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value.
Roger M Lane, Taher Darreh-Shori

J Alzheimers Dis· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies.
Zubin Bhagwagar, Anne Torbeyns, Delphine Hennicken, Ming Zheng, Boadie W Dunlop, Roger Lane

J Clin Psychopharmacol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antidepressant drug development: Focus on triple monoamine reuptake inhibition.
Roger M Lane

J Psychopharmacol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836.
Ming Zheng, Lieuwe Appel, Feng Luo, Roger Lane, David Burt

Psychopharmacology (Berl)· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restoration of positive mood states in major depression as a potential drug development target.
Roger M Lane

J Psychopharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype.
Roger M Lane, Yunsheng He

Alzheimers Dement· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.
Jeffrey Cummings, Murat Emre, Dag Aarsland, Sibel Tekin, Nalina Dronamraju, Roger Lane

J Alzheimers Dis· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease.
Salka S Staekenborg, Tanja Su, Elisabeth C W van Straaten, Roger Lane, Philip Scheltens

J Neurol Neurosurg Psychiatry· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cholinesterase inhibition: is there evidence for disease-modifying effects?
Michael Shanks, Miia Kivipelto, Roger Bullock, Roger Lane

Curr Med Res Opin· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.
Steven Ferris, Agneta Nordberg, Hilkka Soininen, Taher Darreh-Shori, Roger Lane

Pharmacogenet Genomics· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach.
Steven Ferris, Roger Lane, Nikolaos Sfikas, Bengt Winblad, Martin Farlow

Gend Med· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
Hind T Hatoum, Simu K Thomas, Swu-Jane Lin, Roger Lane, Roger Bullock

J Med Econ· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.
Annalena Venneri, Roger Lane

Neuroreport· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis